We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

64 hedge funds and large institutions have $244M invested in Cymabay Therapeutics in 2017 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 6 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more capital invested

Capital invested by funds: $65M → $244M (+$179M)

267% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 6

250% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 10

219% more call options, than puts

Call options by funds: $402K | Put options by funds: $126K

64% more funds holding

Funds holding: 39 → 64 (+25)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
64
Holders Change
+25
Holders Change %
+64.1%
% of All Funds
1.6%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
35
Increased
22
Reduced
6
Closed
10
Calls
$402K
Puts
$126K
Net Calls
+$276K
Net Calls Change
+$247K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$15.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.7M
3
BBA
Baker Bros. Advisors
New York
+$11.5M
4
RG
Redmile Group
California
+$11.1M
5
Franklin Resources
Franklin Resources
California
+$10.1M

Top Sellers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
-$3.74M
2
JGC
J. Goldman & Co
New York
-$1.73M
3
A
Abingworth
United Kingdom
-$387K
4
MWNA
Marshall Wace North America
New York
-$242K
5
ACI
Alpha Cubed Investments
California
-$115K
Name Holding Trade Value Shares
Change 		Change in
Stake
IHM
26
Iguana Healthcare Management
New York
$2.02M +$980K +145,000 +138%
TCM
27
Tekla Capital Management
Massachusetts
$1.69M +$1.42M +209,962 New
BIM
28
Bogle Investment Management
Massachusetts
$1.64M +$1.38M +203,580 New
Ameriprise
29
Ameriprise
Minnesota
$1.54M +$1.29M +190,500 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.25M +$932K +137,830 +795%
GCP
31
GSA Capital Partners
United Kingdom
$1.22M +$1.02M +151,100 New
PPA
32
Parametric Portfolio Associates
Washington
$1.17M +$980K +144,905 New
CM
33
Crestline Management
Texas
$841K +$706K +104,392 New
Northern Trust
34
Northern Trust
Illinois
$711K +$241K +35,653 +68%
Baird Financial Group
35
Baird Financial Group
Wisconsin
$683K +$573K +84,737 New
SCM
36
Sio Capital Management
New York
$605K +$507K +75,000 New
AAP
37
Ardsley Advisory Partners
Connecticut
$566K +$135K +20,000 +40%
Morgan Stanley
38
Morgan Stanley
New York
$460K +$243K +35,946 +171%
BFM
39
Boothbay Fund Management
New York
$404K +$339K +50,077 New
MCM
40
Moore Capital Management
New York
$403K +$338K +50,000 New
Squarepoint
41
Squarepoint
New York
$295K +$127K +18,770 +105%
RJA
42
Raymond James & Associates
Florida
$285K +$239K +35,300 New
State Street
43
State Street
Massachusetts
$279K +$235K +34,700 New
SSA
44
Schonfeld Strategic Advisors
New York
$278K +$233K +34,410 New
EMG
45
Ellington Management Group
Connecticut
$236K +$82.5K +12,200 +71%
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$228K +$101K +14,941 +112%
LCM
47
LVM Capital Management
Michigan
$169K +$6.76K +1,000 +5%
DS
48
DRW Securities
Illinois
$161K +$135K +20,000 New
Tudor Investment Corp
49
Tudor Investment Corp
Connecticut
$129K +$108K +15,978 New
VF
50
Virtu Financial
New York
$128K +$107K +15,836 New
1
2
3

CBAY Hedge Fund Activity: Q3 2017 in Review

64 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2017, worth a combined $244M — up 275% from $65M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new CBAY positions and 10 closed out — a net gain of 25 holders — while 22 added to existing stakes and 6 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $15.9M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $3.74M sold.

  • 64 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2017, up from 39 in Q2 2017.
  • Funds reported $244M of Cymabay Therapeutics stock for Q3 2017, up 275% quarter-over-quarter.
  • 35 funds opened new Cymabay Therapeutics positions in Q3 2017 and 10 closed out, a net change of +25 holders.
  • The largest Cymabay Therapeutics buyer in Q3 2017 was Perceptive Advisors, an estimated $15.9M added.
  • The largest Cymabay Therapeutics seller in Q3 2017 was Ghost Tree Capital, an estimated $3.74M sold.

Based on aggregated 13F filings for Q3 2017.